Search Results

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.

Monte Rosa Therapeutics, Inc. today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.

Monte Rosa Therapeutics, Inc. today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m. ET.

Monte Rosa Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced progress updates for its two lead programs, MRT-2359, an MGD being developed for MYC-driven solid tumors, and MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases.

Monte Rosa Therapeutics, Inc. announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, being held June 12-15 in Vienna, Austria.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the first quarter ending March 31, 2024.